You are here: Industry Insights > Alterity

News List

Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's prnasia
August 05, 2021
Alterity Therapeutics announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Alterity's patent application No. 17/239,375.
Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is Neuroprotective and Improves Motor Function prnasia
July 16, 2021
Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, announced that Movement Disorders, the official journal of the International Parkinson and Movement Disorder Society ...
US grants new patent targeting major neurodegenerative diseases europeanpharmaceuticalreview
July 05, 2021
Alterity Therapeutics have been granted a patent for compounds able to redistribute excess iron in the brain being developed as a treatment for neurodegenerative diseases including Alzheimer’s and Parkinson’s.
Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson's prnasia
July 02, 2021
Alterity Therapeutics has announced the granting of a new composition of matter patent by the United States Patent and Trademark Office (USPTO).
Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial prnasia
June 24, 2021
Alterity Therapeutics Limited has received guidance from the European Medicines Agency (EMA) regarding key aspects of the Company's Phase 2 clinical trial for investigational drug ATH434 in the treatment of Multiple System Atrophy (MSA).
ATH434 protects brain cells and improves motor function in Parkinsonian disorder prnasia
April 22, 2021
Alterity Therapeutics announced an oral presentation of expanded animal data to support the commercialisation of its lead compound ATH434 in clinical development for the treatment of Parkinsonian disorders, at the American Academy of Neurology (AAN) ...
Alterity Therapeutics announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials prnasia
February 10, 2021
Alterity Therapeutics has announced the award of a grant from The Michael J. Fox Foundation for Parkinson's Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson's disease (PD) based on imaging of brain iron.
Alterity and UniQuest partner to reverse bacterial resistance to antibiotics prnasia
December 22, 2020
Alterity Therapeutics has today announced it has been granted a licence by UniQuest, the commercialisation company of The University of Queensland (UQ), to novel zinc ionophore technology to combat antimicrobial resistance in superbugs.
Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases prnasia
November 17, 2020
Alterity Therapeutics has announced the allowance of a new composition of matter patent by the United States Patent and Trademark Office (USPTO).